Cost of bladder cancer in Lebanon before and after the economic collapse: A probabilistic modeling study
Authors:
Preprint
- 7 December 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
Background:Lebanon has one of the highest incidence rates of bladder cancer (BC) in the world. In 2019, Lebanon’s economy collapsed which majorly impacted healthcare costs and coverage. This study assesses the overall direct costs of urothelial BC in Lebanon, from the perspective of public and private third-party payers (TPP) and households, and evaluates the impact of the economic collapse on these costs.Methods:This was a quantitative, incidence-based cost-of-illness study, conducted using a macro-costing approach. Costs of medical procedures were obtained from the records of various TPPs and the Ministry of Public Health. We modeled the clinical management processes for each stage of BC, and conducted probabilistic sensitivity analyses to estimate and compare the cost of each stage, pre-and post-collapse, and for each payer category. The model’s probability parameters were obtained from existing literature and local experts’ opinions, using the conventional Delphi method.Results:Before the collapse, the total annual cost of BC in Lebanon was estimated at LBP 19,676,494,000 (USD 13,117,662). Post-collapse, the use of optimal treatment and management decreased, paralleled with an increase in the proportion of BC patients not undergoing any follow-up. The total annual cost of BC in Lebanon increased by 767.67% and was estimated at LBP 170,727,187,000 (USD 7,422,921). TPP payments increased by 61.42% whereas out-of-pocket (OOP) payments increased by 2,745.33% resulting in a decrease in TPP coverage to only 16.5% of total costs. The cost contribution of low, intermediate and high risk BC slightly decreased whereas the cost contribution of muscle-invasive and metastatic BC slightly increased.Conclusions:Our study shows that BC in Lebanon constitutes a significant economic burden costing 0.32% of total health expenditures. The economic collapse induced an increase of 767.67% in the total annual cost, and a catastrophic increase in OOP payments.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Differences in the recurrence pattern after neoadjuvant chemotherapy compared to surgery alone in patients with muscle-invasive bladder cancerMedical Oncology, 2014
- Sex differences in incidence and mortality of bladder and kidney cancers: National estimates from 49 countriesUrologic Oncology: Seminars and Original Investigations, 2014
- Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder CancerNew England Journal of Medicine, 2012
- Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 2009
- Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 TrialEuropean Urology, 2007
- Delay in the Surgical Treatment of Bladder Cancer and Survival: Systematic Review of the LiteratureEuropean Urology, 2006
- The Delphi technique in health sciences education researchMedical Teacher, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Economic Note: Cost of illness studiesBMJ, 2000
- Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at DiagnosisMedical Care, 1995